Barclays PLC Arcus Biosciences, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 118,693 shares of RCUS stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

118,693

Previous 118,693 -0.0%

Holding current value

$1.74 Million

Previous $1.82 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$13.69 - $18.01 $534,115 - $702,660	39,015 Added 48.97%	118,693 $1.82 Million
Q2 2024 Aug 14, 2024	SELL	$14.59 - $18.48 $1.58 Million - $2 Million	-108,193 Reduced 57.59%	79,678 $1.21 Million
Q1 2024 May 15, 2024	SELL	$14.83 - $20.18 $222,776 - $303,143	-15,022 Reduced 7.4%	187,871 $3.55 Million
Q4 2023 Feb 15, 2024	SELL	$13.43 - $19.63 $3.6 Million - $5.26 Million	-267,883 Reduced 56.9%	202,893 $3.88 Million
Q3 2023 Nov 07, 2023	BUY	$17.62 - $23.54 $5.37 Million - $7.17 Million	304,683 Added 183.44%	470,776 $8.45 Million
Q2 2023 Aug 03, 2023	BUY	$16.97 - $22.03 $61,804 - $80,233	3,642 Added 2.24%	166,093 $3.37 Million
Q1 2023 May 04, 2023	BUY	$15.96 - $23.15 $581,151 - $842,960	36,413 Added 28.89%	162,451 $2.96 Million
Q4 2022 Feb 13, 2023	SELL	$19.7 - $35.71 $840,638 - $1.52 Million	-42,672 Reduced 25.29%	126,038 $2.61 Million
Q3 2022 Nov 03, 2022	BUY	$23.23 - $30.07 $3.09 Million - $4 Million	133,006 Added 372.52%	168,710 $4.41 Million
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $88,355 - $193,479	5,128 Added 16.77%	35,704 $905,000
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $790,557 - $1.14 Million	-27,336 Reduced 47.2%	30,576 $965,000
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $65,960 - $101,883	2,102 Added 3.77%	57,912 $2.34 Million
Q3 2021 Nov 09, 2021	BUY	$26.93 - $37.68 $1.34 Million - $1.87 Million	49,753 Added 821.41%	55,810 $1.95 Million
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $1.51 Million - $2.38 Million	-66,514 Reduced 91.65%	6,057 $166,000
Q1 2021 May 13, 2021	BUY	$26.16 - $41.39 $693,161 - $1.1 Million	26,497 Added 57.51%	72,571 $2.04 Million
Q4 2020 Feb 11, 2021	SELL	$17.0 - $32.36 $202,487 - $385,439	-11,911 Reduced 20.54%	46,074 $1.2 Million
Q3 2020 Nov 12, 2020	BUY	$17.14 - $25.47 $100,029 - $148,642	5,836 Added 11.19%	57,985 $995,000
Q2 2020 Aug 12, 2020	BUY	$13.97 - $36.56 $520,172 - $1.36 Million	37,235 Added 249.66%	52,149 $1.29 Million
Q1 2020 May 13, 2020	SELL	$8.78 - $19.28 $195,995 - $430,387	-22,323 Reduced 59.95%	14,914 $207,000
Q4 2019 Feb 10, 2020	BUY	$7.33 - $10.79 $110,125 - $162,108	15,024 Added 67.64%	37,237 $376,000
Q3 2019 Nov 14, 2019	SELL	$6.44 - $10.18 $182,844 - $289,030	-28,392 Reduced 56.11%	22,213 $203,000
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $292,576 - $536,992	40,134 Added 383.29%	50,605 $402,000
Q1 2019 May 15, 2019	BUY	$8.95 - $12.49 $79,395 - $110,798	8,871 Added 554.44%	10,471 $131,000
Q4 2018 Feb 14, 2019	SELL	$9.74 - $14.5 $39,213 - $58,377	-4,026 Reduced 71.56%	1,600 $17,000
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.95 $25,796 - $35,446	2,371 Added 72.84%	5,626 $78,000
Q2 2018 Aug 14, 2018	BUY	$12.24 - $17.05 $39,841 - $55,497	3,255 New	3,255 $41,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.7M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account